论文部分内容阅读
目的总结性探讨分析2种不同利福布丁给药方案治疗耐多药结核病的临床疗效。方法 120例耐多药结核病患者,随机分为观察组和对照组,各60例。对照组的治疗方法为3BPa VETh Ak/6BPa VETh/9Bpa VE[继续期治疗月数(9),巩固期治疗月数(6),强化期治疗月数(3),利福布丁(B),帕司烟阱(Pa),左氧氟沙星(V),乙胺丁醇(E),丙硫异烟胺(Th),丁胺卡那霉素(Ak)];观察组的治疗方法为3B3Pa VETh Ak/6B3Pa VETh/9B3Pa VE。观察比较两组治疗效果。结果治疗前后两组患者的临床症状积分比较,差异有统计学意义(P<0.05),但是治疗后组间比较差异无统计学意义(P>0.05)。两组患者痰菌阴转情况比较,差异无统计学意义(P>0.05)。结论利福布丁不同的给药方案不会对治疗耐多药结核病的疗效产生差异,值得临床推广应用。
Objective To summarize and analyze the clinical effects of two different rifabutin dosing regimens in the treatment of multidrug-resistant tuberculosis. Methods A total of 120 MDR-TB patients were randomly divided into observation group and control group, with 60 cases in each. The control group was treated with 3B Pa VETh Ak / 6BPa VETh / 9Bpa VE [months of continued treatment (9), months of consolidation (6), months of intensive treatment (3), rifabutin (B) Paclitaxel (Pa), Levofloxacin (V), Ethambutol (E), Thiramine (Th) and Amikacin (Ak)). The observation group was treated with 3B3 Pa VETh Ak / 6B3Pa VETh / 9B3Pa VE. Observed and compared the treatment effect. Results Before and after treatment, the clinical symptom scores of two groups were statistically significant (P <0.05), but there was no significant difference between the two groups after treatment (P> 0.05). There was no significant difference in sputum negative conversion between the two groups (P> 0.05). Conclusion Different doses of rifabutin will not be effective in treating MDR-TB, which is worthy of clinical application.